The investments include three companies that have novel immunotherapies in early human clinical trials and two companies with promising programs in preclinical development for blood cancers: Caribou Biosciences, NexImmune, Immune-Onc Therapeutics, Carisma Therapeutics, and Abintus Bio.

LLS has dedicated more than $100 million over the past several decades, through both grants and TAP investments, to advancing pioneering approaches that harness cellular immunotherapies to fight blood cancers.

Caribou nabs $115M to advance CRISPR-edited cell therapies
Caribou Biosciences has completed $115 million in financing to further develop its next-generation CRISPR technology platform and advance its pipeline...

AbbVie, Caribou enter deal to develop CAR T-cell therapies
AbbVie and Caribou Biosciences have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)...

Tackling the next hurdle in cell and gene therapy: Manufacturing
Although innovation continues to occur at lightning fast speeds in the cell and gene therapy space, commercialization and manufacturing of these technologies...

Carisma, NYU Langone to develop Vpx lentiviral vector
Carisma Therapeutics has entered into a scientific research and licensing agreement with NYU Langone Health to attain exclusive rights to develop and...

Carisma advances macrophage immunotherapy
Carisma Therapeutics' engineered macrophage immunotherapy has cleared an investigational new drug application through the U.S. Food and Drug Administration....